Literature DB >> 21437762

Validated tools for evaluating opioid-induced bowel dysfunction.

Anne Estrup Olesen1, Asbjørn Mohr Drewes.   

Abstract

Adverse effects on the gastrointestinal system are problematic for pain patients receiving opioid treatment. Opioid-induced bowel dysfunction (OIBD) is often misinterpreted as constipation as this is the most frequently reported symptom of OIBD; however, it actually comprises the whole gut with symptoms such as nausea, reflux, bloating, and anorexia being very prevalent as well. Validated methods to evaluate these symptoms are essential before the action of a drug on bowel dysfunction can be evaluated, but only the effect on the most frequently reported symptom, constipation, has been evaluated systematically. Constipation is a personal symptom and there is little correlation between subjective methods for assessment of constipation and objective evaluations, such as transit time and fecal loading. Few questionnaires specific to constipation exist, since most that are regularly used form part of general gastrointestinal investigations, which furthermore are often complicated and time consuming to complete. This article gives an overview of the different evaluation regimes for OIBD with a particular focus on the most frequently reported symptom; constipation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21437762     DOI: 10.1007/s12325-011-0006-4

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  11 in total

Review 1.  Evolving paradigms in the treatment of opioid-induced bowel dysfunction.

Authors:  Jakob Lykke Poulsen; Christina Brock; Anne Estrup Olesen; Matias Nilsson; Asbjørn Mohr Drewes
Journal:  Therap Adv Gastroenterol       Date:  2015-11       Impact factor: 4.409

Review 2.  The role of naloxegol in the management of opioid-induced bowel dysfunction.

Authors:  Wojciech Leppert; Jaroslaw Woron
Journal:  Therap Adv Gastroenterol       Date:  2016-05-26       Impact factor: 4.409

3.  Prolonged-Release Oxycodone/Naloxone Improves Anal Sphincter Relaxation Compared to Oxycodone Plus Macrogol 3350.

Authors:  Jakob Lykke Poulsen; Christina Brock; Debbie Grønlund; Donghua Liao; Hans Gregersen; Klaus Krogh; Asbjørn Mohr Drewes
Journal:  Dig Dis Sci       Date:  2017-10-06       Impact factor: 3.199

Review 4.  Opioid-induced bowel dysfunction: pathophysiology and management.

Authors:  Christina Brock; Søren Schou Olesen; Anne Estrup Olesen; Jens Brøndum Frøkjaer; Trine Andresen; Asbjørn Mohr Drewes
Journal:  Drugs       Date:  2012-10-01       Impact factor: 9.546

Review 5.  Clinical utility of naloxegol in the treatment of opioid-induced constipation.

Authors:  Heather C Bruner; Rabia S Atayee; Kyle P Edmonds; Gary T Buckholz
Journal:  J Pain Res       Date:  2015-06-12       Impact factor: 3.133

Review 6.  Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction.

Authors:  Wojciech Leppert
Journal:  Drug Des Devel Ther       Date:  2015-04-16       Impact factor: 4.162

Review 7.  Clinical potential of naloxegol in the management of opioid-induced bowel dysfunction.

Authors:  Jakob Lykke Poulsen; Christina Brock; Anne Estrup Olesen; Matias Nilsson; Asbjørn Mohr Drewes
Journal:  Clin Exp Gastroenterol       Date:  2014-09-19

8.  Colorectal Transit and Volume During Treatment With Prolonged-release Oxycodone/Naloxone Versus Oxycodone Plus Macrogol 3350.

Authors:  Jakob L Poulsen; Esben B Mark; Christina Brock; Jens B Frøkjær; Klaus Krogh; Asbjørn M Drewes
Journal:  J Neurogastroenterol Motil       Date:  2018-01-30       Impact factor: 4.924

9.  The Impact of Opioid Treatment on Regional Gastrointestinal Transit.

Authors:  Jakob L Poulsen; Matias Nilsson; Christina Brock; Thomas H Sandberg; Klaus Krogh; Asbjørn M Drewes
Journal:  J Neurogastroenterol Motil       Date:  2016-04-30       Impact factor: 4.924

Review 10.  Naloxegol in opioid-induced constipation: a new paradigm in the treatment of a common problem.

Authors:  Stephanie C Yoon; Heather C Bruner
Journal:  Patient Prefer Adherence       Date:  2017-07-24       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.